title: Systemically elevated Th1-, Th2- and Th17-associated chemokines in psoriasis vulgaris before and after ultraviolet B treatment.
abstract: Chemokines may contribute to the systemic inflammation that is linked to the increased risk of co-morbidities in patients with psoriasis. The aim of this study was to investigate circulating chemokines in patients with psoriasis and their relationship to disease severity. Analysis of plasma levels of chemokines in patients with psoriasis before narrowband ultraviolet B (UVB) therapy revealed increased expression of Th1-associated CXCL9 and -10, Th2-associated CCL17 and CCL22, and Th17-associated CCL20. CCL20 correlated with disease severity. UVB therapy reduced skin symptoms, but did not affect the chemokine levels in plasma. Anti-CD3 and anti-CD28-mediated activation of peripheral blood mononuclear cells (PBMCs) caused a higher secretion of Th2 cytokine interleukin (IL)-13 by PBMCs from patients with psoriasis than from healthy controls. The sustained high expression of inflammatory chemokines is a potential link to systemic inflammation in psoriasis. UVB therapy may be a more effective treatment of local rather than systemic inflammation.
authors.affiliation: Ingrid Asp Psoriasis Research Center, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, Linköping, Sweden.
authors.forename: Anna-Karin
authors.initials: AK
authors.lastname: Ekman
authors.forename: Gunnthorunn
authors.initials: G
authors.lastname: Sigurdardottir
authors.forename: Maria
authors.initials: M
authors.lastname: Carlström
authors.forename: Natalja
authors.initials: N
authors.lastname: Kartul
authors.forename: Maria C
authors.initials: MC
authors.lastname: Jenmalm
authors.forename: Charlotta
authors.initials: C
authors.lastname: Enerbäck
mesh_terms: D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D002478:Cells, Cultured; D018925:Chemokines / Q000097:blood*; D005260:Female; D006801:Humans; D018836:Inflammation Mediators / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000097:blood / Q000453:epidemiology / Q000532:radiotherapy*; D012720:Severity of Illness Index; D018417:Th1 Cells / Q000276:immunology / Q000528:radiation effects*; D058504:Th17 Cells / Q000276:immunology / Q000528:radiation effects*; D018418:Th2 Cells / Q000276:immunology / Q000528:radiation effects*; D013997:Time Factors; D016896:Treatment Outcome; D014467:Ultraviolet Therapy; D015854:Up-Regulation; D055815:Young Adult
chemical_list: D015415:Biomarkers; D018925:Chemokines; D018836:Inflammation Mediators